Department of Chemical Sciences, SSPC the SFI Pharmaceutical Centre, Bernal Institute, University of Limerick, Limerick, Ireland.
Expert Opin Drug Deliv. 2020 May;17(5):677-688. doi: 10.1080/17425247.2020.1743677. Epub 2020 Mar 31.
: Given that hydrophobic active pharmaceutical ingredients (APIs) intended for oral delivery comprised about 68% of US FDA approvals in 2019 alone, the impact of endogenous gastrointestinal (GI) molecules on their inherently unstable solution behavior needs to be elucidated.: The interactions between hydrophobic API's and GI phospholipids, bile acids/salts and digestive proteins are explored. The impact of the complex relationship between the GI molecules and hydrophobic APIs on solubilization by micelle formation, complexation or by inhibiting the nucleation of high energy forms of hydrophobic APIs, so called supersaturating drug delivery systems is complex. The ability of these endogenous GI molecules to manipulate the solution behavior of hydrophobic APIs has been demonstrated both at their native concentrations and when included as exogenous formulation additives. Specific studies of the impact of proteins and mixed micelles on solubilization and crystallization are reported.: Elucidation of the complex molecular interactions between orally administered hydrophobic APIs and endogenous GI molecules will enable better correlation and potentially lead to formulation strategies that avoid the stochastic nature of hydrophobic API precipitation in the GI tract.
: 鉴于 2019 年美国 FDA 批准的用于口服给药的疏水性活性药物成分 (API) 中约有 68%,需要阐明内源性胃肠道 (GI) 分子对其固有不稳定溶液行为的影响。探讨了疏水性 API 与 GI 磷脂、胆汁酸/盐和消化蛋白之间的相互作用。GI 分子与疏水性 API 之间复杂关系对胶束形成、络合或抑制疏水性 API 高能形式成核(所谓的超饱和药物传递系统)的增溶的影响是复杂的。这些内源性 GI 分子在其天然浓度以及作为外源性制剂添加剂包含时,已经证明了其能够操纵疏水性 API 的溶液行为。报道了蛋白质和混合胶束对增溶和结晶影响的具体研究。阐明口服给予的疏水性 API 与内源性 GI 分子之间的复杂分子相互作用将能够更好地进行相关性,并可能导致避免 GI 道中疏水性 API 沉淀的随机性的配方策略。